Aminopeptidase N (CD13, EC 3.4.11.2) Occurs on the Surface of Resting and Concanavalin A-Stimulated Lymphocytes
- 1 January 1993
- journal article
- research article
- Published by Walter de Gruyter GmbH in Biological Chemistry Hoppe-Seyler
- Vol. 374 (1-6) , 291-296
- https://doi.org/10.1515/bchm3.1993.374.1-6.291
Abstract
Using different approaches evidence is provided that aminopeptidase N (APN, EC 3.4.11.2, CD13) is expressed on the surface of resting and stimulated human lymphocytes. 1) 50% of total Ala-pNA hydrolysis of viable cells was found to be due to the ectoenzyme APN as revealed by titration with the new inhibitor probestin in comparison to purified APN from human kidney (Ki value 6.5 nM). After stimulation with ConA an increase of Ala-pNA hydrolysis was observed from 8 pkat up to 15 pkat/10(6) cells. 2) This correlated with an increase of APN (CD13) surface expression as detected by antibody surface labeling of unstimulated (5-12% CD13 positive cells) and stimulated lymphocytes (28-36% CD13 positive lymphocytes) using polyclonal and monoclonal antibodies. 3) In vivo APN was found to be expressed on the surface of up to 50% lymphocytes isolated from the synovial fluid of rheumatoid patients.Keywords
This publication has 6 references indexed in Scilit:
- CD13 Expression in B-Cell Chronic Lymphocytic Leukemia is Associated with the Pattern of Bone Marrow InfiltrationLeukemia & Lymphoma, 1992
- N-linked neutral sugar chains of aminopeptidase N purified from rat small intestinal brush-border membraneBiochemistry, 1991
- Probestin, a new inhibitor of aminopeptidase M, produced by Streptomyces azureus MH663-2F6. I. Taxonomy, production, isolation, physico-chemical properties and biological activities.The Journal of Antibiotics, 1990
- Human myeloid plasma membrane glycoprotein CD13 (gp150) is identical to aminopeptidase N.Journal of Clinical Investigation, 1989
- Early Expression of MCS2 (CD 13) in the Cytoplasm of Blast Cells from Acute Myeloid LeukaemiaActa Haematologica, 1988
- Inhibition of aminopeptidases by amastatin and bestatin derivatives. Effect of inhibitor structure on slow-binding processesJournal of Medicinal Chemistry, 1984